ON THE INTRAINDIVIDUAL VARIABILITY AND CHRONOBIOLOGY OF CYCLOSPORINE PHARMACOKINETICS IN RENAL-TRANSPLANTATION

被引:61
作者
OHLMAN, S
LINDHOLM, A
HAGGLUND, H
SAWE, J
KAHAN, BD
机构
[1] HUDDINGE HOSP,KAROLINSKA INST,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[2] UNIV TEXAS,SCH MED,DEPT SURG,DIV IMMUNOL & ORGAN TRANSPLANTAT,HOUSTON,TX 77025
关键词
CYCLOSPORINE; RENAL TRANSPLANTATION; PHARMACOKINETICS; INTRAINDIVIDUAL VARIATION; CIRCADIAN VARIATION;
D O I
10.1007/BF00271369
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intraindividual variability and circadian variation of oral cyclosporine (CsA) pharmacokinetics were studied over 24 h in 18 renal transplant recipients at steady state, and in 10 of the patients during a second 24 h period. The absolute percentage intraindividual difference in daytime AUC (0-12 h) ranged from 2 % to 54 % (mean 30%), and the corresponding variability in nighttime AUC (0-12 h) ranged from 5 % to 80 % (mean 34 %). The pharmacokinetic variables t1/2, t(max) and C(max) were more variable than the AUC (0-12 h) both during the day and at night. The evening trough level was significantly lower than the morning trough level; 185 ng.ml-1 versus 223 ng.ml-1. This, together with a significantly longer t1/2 in the night than the day, suggested circadian variability in the pharmacokinetics of CsA. In a separate retrospective study in 162 renal transplant recipients given CsA by constant intravenous infusion, repeated CsA blood concentration measurements at steady state showed lower concentrations during the day than the night, suggesting higher CsA clearance during daytime. It is concluded that CsA pharmacokinetics in renal transplant recipients, besides the well-known interindividual variability, also displays large intraindividual variability as well as circadian variation. Our findings further emphasize the necessity and difficulty of pharmacological monitoring in the clinical use of CsA in organ transplantation.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 1983, LANCET, V2, P986
[2]  
BOWERS LD, 1986, TRANSPLANT P, V18, P137
[3]   CYCLOSPORINE ABSORPTION FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION [J].
BURCKART, GJ ;
VENKATARAMANAN, R ;
PTACHCINSKI, RJ ;
STARZL, TE ;
GARTNER, JC ;
ZITELLI, BJ ;
MALATACK, JJ ;
SHAW, BW ;
IWATSUKI, S ;
VANTHIEL, DH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08) :647-651
[4]   TROUGH LEVELS AND CONCENTRATION-TIME CURVES OF CYCLOSPORINE IN PATIENTS UNDERGOING RENAL-TRANSPLANTATION [J].
FREY, FJ ;
HORBER, FF ;
FREY, BM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (01) :55-62
[5]   PHARMACOKINETICS OF CYCLOSPORINE - INFLUENCE OF RATE OF CONSTANT INTRAVENOUS-INFUSION IN RENAL-TRANSPLANT PATIENTS [J].
GUPTA, SK ;
LEGG, B ;
SOLOMON, LR ;
JOHNSON, RWG ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (04) :519-526
[6]   THE ABILITY OF PRETRANSPLANT TEST-DOSE PHARMACOKINETIC PROFILES TO REDUCE EARLY ADVERSE EVENTS AFTER RENAL-TRANSPLANTATION [J].
KAHAN, BD ;
WELSH, M ;
RUTZKY, L ;
LEWIS, R ;
KNIGHT, R ;
KATZ, S ;
NAPOLI, K ;
GREVEL, J ;
VANBUREN, CT .
TRANSPLANTATION, 1992, 53 (02) :345-351
[7]   OPTIMIZATION OF CYCLOSPORINE THERAPY IN RENAL-TRANSPLANTATION BY A PHARMACOKINETIC STRATEGY [J].
KAHAN, BD ;
GREVEL, J .
TRANSPLANTATION, 1988, 46 (05) :631-644
[8]   CYCLOSPORINE PLASMA-LEVELS IN RENAL-TRANSPLANT PATIENTS - ASSOCIATION WITH RENAL TOXICITY AND ALLOGRAFT-REJECTION [J].
KLINTMALM, G ;
SAWE, J ;
RINGDEN, O ;
VONBAHR, C ;
MAGNUSSON, A .
TRANSPLANTATION, 1985, 39 (02) :132-137
[9]   THERAPEUTIC MONITORING OF CYCLOSPORINE - AN UPDATE [J].
LINDHOLM, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (04) :273-283
[10]   INTRAINDIVIDUAL VARIABILITY IN THE RELATIVE SYSTEMIC AVAILABILITY OF CYCLOSPORIN AFTER ORAL DOSING [J].
LINDHOLM, A ;
HENRICSSON, S ;
LIND, M ;
DAHLQVIST, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :461-464